Flutialfa S 250 Inhaler is a combination inhalation therapy that brings together the potent anti-inflammatory effects of Fluticasone Propionate (250 mcg) with the long-acting bronchodilatory action of Salmeterol Xinafoate (25 mcg). This dual-action inhaler is designed to provide effective and sustained control of asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Fluticasone Propionate is a synthetic corticosteroid that reduces airway inflammation, swelling, and mucus production, thereby minimizing asthma symptoms and improving respiratory function. It works by inhibiting multiple types of inflammatory cells and mediators involved in the allergic and non-allergic response in the airways.
Salmeterol Xinafoate is a long-acting beta-2 adrenergic agonist (LABA) that relaxes the muscles in the airways, facilitating smoother airflow into the lungs. It helps prevent wheezing, breathlessness, chest tightness, and coughing associated with chronic respiratory disorders. When used together, these ingredients provide both immediate and long-term control of symptoms, reducing the frequency of exacerbations and improving overall lung function.
Flutialfa S 250 Inhaler is typically used twice daily and is ideal for patients requiring maintenance therapy. It is not intended for the relief of acute asthma attacks but serves as a cornerstone in the long-term management plan prescribed by a healthcare professional.
This inhaler is engineered with a metered-dose mechanism that ensures accurate and consistent delivery of the medication. Regular use as per medical guidance helps in improving quality of life and reducing emergency hospital visits in asthma and COPD patients.